Loading...
Modulation of biomarker expression by Osimertinib: results of the paired tumor biopsy cohorts of the AURA Phase I trial.
Thress, K Jacobs, V Angell, H Chih-Hsin Yang, J Sequist, L Su, W Schuler, M Wolf, J Gold,K
Thress, K
Jacobs, V
Angell, H
Chih-Hsin Yang, J
Sequist, L
Su, W
Schuler, M
Wolf, J
Gold,K
Citations
Altmetric:
Abstract
Osimertinib is an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR TKI and T790M resistance mutations. To enhance understanding of osimertinib's mechanism of action, we aimed to evaluate the modulation of key molecular biomarkers after osimertinib treatment in paired clinical samples from the phase I AURA trial.
Affiliation
Description
Date
2017-07-24
Publisher
Collections
Files
Loading...
pdf.pdf
Adobe PDF, 308.49 KB
Keywords
Type
Article
Citation
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. 2017 J Thorac Oncol